Premium
Cilobamine in the treatment of atypical depression
Author(s) -
Wager Steven,
Quitkin Frederic,
Stewart Jonathan,
McGrath Patrick,
Harrison Wilma,
Markowitz Jeffrey,
Tricamo Elaine
Publication year - 1988
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470030308
Subject(s) - atypical depression , placebo , depression (economics) , antidepressant , monoamine oxidase , tricyclic , medicine , monoamine oxidase inhibitor , hamilton depression scale , tricyclic antidepressant , mesylate , psychiatry , hamd , pharmacology , significant difference , alternative medicine , pathology , biology , chemistry , biochemistry , appetite , organic chemistry , hippocampus , economics , macroeconomics , enzyme
Sixteen patients meeting our criteria for atypical depression were treated in a 7‐week single‐blind pilot study with cilobamine mesylate, an investigational antidepressant structurally distinct from tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI). Nine patients (56 per cent) responded to cilobamine. Cilobamine patients were compared with a group of similar patients receiving placebo for 6 weeks in a separate double‐blind study. The response rate to cilobamine was superior to that of placebo. Cilobamine patients also showed significantly greater improvement in Hamilton Depression Scale scores than did placebo patients. Previous studies have demonstrated the efficacy of MAOIs in atypical depression. This study suggests that certain antidepressants which are not MAOIs, and are free of dietary restrictions and the risk of hypertensive crises, may also be effective in atypical depression.